semaglutide and heart issues cardiovascular outcomes align more closely with attained dose than achieved weight loss Cardiovascular outcomes of semaglutide and

Gallbladder disease: Rapid weight loss is associated with an increased risk of gallstones and gallbladder inflammation (cholecystitis)

A prescription GLP-1 medication requires years of clinical trials, FDA review, and post-market surveillance

Among these, diet has the most significant impact on the gut microbiota (157)

Dries in a pinch and super hydrating

The FDA has found heavy metals, bacterial toxins (endotoxins), wrong peptide sequences, and contamination in seized samples of GLP-1 peptides sold online

This concern appears to stem from glutathione's skin-brightening mechanism, which works by inhibiting melanin production through tyrosinase modulation a temporary, dose-dependent, and generally reversible effect, not an autoimmune depigmentation process like vitiligo